The association of vagina equivalent dose in 2Gy fraction(EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220209011

Enrollment

Registered

2022-02-09

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer brachytherapy, cervical cancer, dose-effect, PIBS-2, mean dose of lateral 5mm vagina, radiotherapy, vaginal stenosis

Interventions

Patients with grade 2 or higher vaginal stenosis,Patients with grade 0-1 vaginal stenosis

Treatment,Treatment

Grade 2+ vaginal stenosis,Grade 0-1 vaginal stenosis

Eligibility

Sex/Gender

Female

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with cervical cancer who were treated with IGBT from January 2015 to July,2020.

Exclusion criteria

Exclusion criteria: Excluded patients with history of previous pelvic radiation and patient treated with tandem & mould applicator

Design outcomes

Primary

Measure	Time frame
vaginal stenosis at least 6 mo after treatment Grading by Modified Dische score	—

Secondary

Measure	Time frame
quality of life score at least 6 month after treatment EORTC QLQ Cx24 score	—

Countries

Thailand

Contacts

Public ContactJintana Runala

Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University

Jane_neee@hotmail.com0954501802

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026